Fig. 1
From: PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
PRMT5 expression is upregulated and indicates a worse prognosis in pancreatic cancer patients a. PRMT5 expression was upregulated in PDAC tumor samples compared with that in normal adjacent samples, as indicated by real-time PCR and paired t-test analysis. b. Immunohistochemical staining of PRMT5 in PDAC tumor samples and paired adjacent normal tissues. c. PRMT5 protein levels were increased in tumor samples, as reflected by IHC analysis. d. IHC scoring of PRMT5 expression in pancreatic cancer tissues, which were divided into the low PRMT5 expression and high PRMT5 expression subgroups. e. Patients in the FDUSCC cohort with high PRMT5 expression had shorter overall survival times than those with low PRMT5 expression. f. PRMT5 expression in the TCGA-PAAD RNA-seq dataset. Analysis results demonstrated that high PRMT5 expression predicts a shorter OS time. g. Patients with high PRMT5 expression had shorter DFS times than patients with low PRMT5 expression